News | Mammography | March 30, 2016

FDA Revokes MQSA Certificate of California Mammography Facility

Facility was subject of previous FDA Safety Notification on poor mammogram quality; patients who received mammograms on or after Sept. 8, 2014, advised to have results re-evaluated elsewhere

FDA alert, Huntington Radiology, California, MQSA certificate revoked

March 30, 2016 — The U.S. Food and Drug Administration (FDA) revoked the Mammography Quality Standards Act (MQSA) certificate of J. Bruce Jacobs M.D. Inc., doing business as Huntington Radiology in Huntington Park, Calif., on March 4. The FDA is alerting patients who had mammograms at the facility any time on or after Sept. 8, 2014, about possible problems with the quality of their mammograms.

This facility was the subject of a prior FDA Safety Notification issued on March 10, 2011.

The American College of Radiology (ACR) conducted a review of mammograms performed at the facility between Sept. 8, 2014, and Nov. 4, 2014. The clinical image review was conducted for the purposes of accreditation reinstatement following the Aug. 31, 2010, ACR revocation of the facility’s accreditation. On Sept. 8, 2014, the facility was provisionally certified to provide mammography services; however, a subsequent ACR clinical image review indicated problems with the quality of the mammography at the facility. The ACR revoked the facility's application for accreditation effective Feb. 20, 2015, and the FDA suspended the facility’s certificate on March 6, 2015.

On April 8, 2015, the FDA required the facility to notify all patients who received mammograms at its facility any time on or after Sept. 8, 2014, and their referring healthcare providers, about the problems with the mammography quality at the facility.

In accordance with its rules and requirements the State of California, Health and Human Services Agency, California Department of Public Health issued a Cease and Desist Order against the facility on Feb. 9, 2015, based on a state investigation and the findings noted by the ACR during the Additional Mammography Review (AMR).

Under the MQSA of 1992, the FDA requires that all mammography facilities meet certain baseline quality standards and be certified to legally operate in the United States. This facility did not meet standards for mammography quality under the Act. The facility may not legally perform mammography at this time due to the suspension of its certificate.

This does not mean that the results of the mammograms were inaccurate, but it does mean that the patients should consider having their mammograms re-evaluated at an MQSA-certified facility to determine if the patients need a repeat mammogram or additional medical follow-up.

The FDA will continue to monitor this issue and keep the public informed as new information becomes available.

For more information: www.fda.gov

Related Content

SmartCurve technology, a revolutionary breast imaging technology designed specifically for the curvature of the female breast to provide every woman with a more comfortable and accurate mammogram.
News | Mammography | September 14, 2018
Solis Mammography declared September Breast Wellness Month a
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...